In a UK-wide survey, 28% of neonatal units reported using systemic or topical/oral antifungal prophylaxis for very low birthweight infants. Systemic prophylaxis is targeted to extremely preterm infants with additional risk factors for invasive fungal infection. Currently, there seems to be sufficient variation in practice to undertake randomised trials of these interventions.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: The authors have previously received an educational grant from Pfizer UK Ltd, a manufacturer of fluconazole. This company had no role in the collection, analysis and interpretation of data, or in the writing of the report or decision to submit for publication.